Accueil   Diary - News   All news PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

 

B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed

 

 

Liège, Belgium, and Grenoble, France, November 4, 2021 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces that the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 phase I/II clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).

 


PDC*lung01 is a cell suspension of a mix, in the same proportion, of seven active agents - made of irradiated human plasmacytoïd dendritic cells (PDC*line), loaded separately with a distinct synthetic human leukocyte antigen serotype-restricted peptide - (HLA-A*02:01), encoded by a tumor antigen. PDC*line is a potent professional antigen-presenting cell that is able to prime and boost the antitumor cytotoxic CD8+ T-cells in the patient’s immune system.

 

Read the press release